A Phase 2 Multicenter Open-label Study Evaluating the Safety and Efficacy of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer (CRPC) and a Rising Prostate-specific Antigen (PSA).
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2014
At a glance
- Drugs Orteronel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 10 Jun 2017 Biomarkers information updated
- 23 Jan 2013 Planned End Date changed from 1 May 2015 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 04 Jun 2012 Results were reported at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Millennium media release.